1. Percutaneous image guided electrochemotherapy of hepatocellular carcinoma : technological advancementMihajlo Djokić, Rok Dežman, Maja Čemažar, Miha Štabuc, Miha Petrič, Lojze Šmid, Rado Janša, Boštjan Plešnik, Maša Omerzel, Urša Lampreht Tratar, Blaž Trotovšek, Bor Kos, Damijan Miklavčič, Gregor Serša, Peter Popović, 2020, original scientific article Abstract: Background. Electrochemotherapy is an effective treatment of colorectal liver metastases and hepatocellular carcinoma (HCC) during open surgery. The minimally invasive percutaneous approach of electrochemotherapy has already been performed but not on HCC. The aim of this study was to demonstrate the feasibility, safety and effectiveness of electrochemotherapy with percutaneous approach on HCC. Patient and methods. The patient had undergone the transarterial chemoembolization and microwave ablation of multifocal HCC in segments III, V and VI. In follow-up a new lesion was identified in segment III, and recognized by multidisciplinary team to be suitable for minimally invasive percutaneous electrochemotherapy. The treatment was performed with long needle electrodes inserted by the aid of image guidance. Results. The insertion of electrodes was feasible, and the treatment proved safe and effective, as demonstrated by control magnetic resonance imaging. Conclusions. Minimally invasive, image guided percutaneous electrochemotherapy is feasible, safe and effective in treatment of HCC.
Keywords: electrochemotherapy, hepatocellular carcinoma, percutaneous, minimally invasive
Published in DiRROS: 12.07.2024; Views: 64; Downloads: 12
 Full text (1,52 MB) |
2. Sorafenib for the treatment of hepatocellular carcinoma : a single-centre real-world studyJurij Hanžel, Tajda Božič, Borut Štabuc, Rado Janša, 2020, original scientific article Abstract: Background Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma. Its efficacy in randomised controlled trials was demonstrated in patients with well-preserved liver function and good functional status. In the real-world setting, treatment is often offered to patients outside these criteria. We therefore performed a single-centre real-world cohort study on the efficacy of sorafenib in patients with hepatocellular carcinoma. Patients and methods We identified all patients with hepatocellular carcinoma initiating treatment with sorafenib between January 2015 and January 2018. The primary endpoint was overall survival (OS) since starting sorafenib. Clinical and demographic variables associated with survival were studied. Results The median OS was 13.4 months (95% CI 8.2%18.6). Multivariable Cox%s regression identified worse ECOG performance status (HR 2.21; 95% CI 1.56%3.16; P < 0.0001), Child-Pugh class C (HR 52.4; 95% CI 3.20%859; P = 0.005) and absence of prior locoregional treatment (HR 2.30; 95% CI 1.37%3.86; P = 0.002) to be associated with increased mortality. Conclusions Careful selection of patients for treatment with sorafenib is of paramount importance to optimize outcomes.
Keywords: hepatocellular carcinoma, survival, sorafenib
Published in DiRROS: 12.07.2024; Views: 63; Downloads: 32
Full text (583,71 KB)
This document has many files! More... |
3. |
4. Slovenska priporočila za obravnavo odraslih bolnikov s kronično odpovedjo prebavilNada Rotovnik-Kozjek, Tajda Božič, Katja Kogovšek, Borut Štabuc, Laura Petrica, Karla Berlec, Nataša Puzić Ravnjak, Erik Brecelj, Aleš Tomažič, Sanela Banović, Rada Franko, Milena Kovač-Blaž, Janez Breznik, Davorin Ćeranić, David Drobne, Mojca Gašperin, Tomaž Jurca, Maja Ebert Moltara, Rado Janša, Marjana Turk Jerovšek, Taja Jordan, Tina Kamhi, Primož Karner, Milena Kerin-Povšič, Neža Majdič, Denis Mlakar-Mastnak, Andreja Ocepek, Tadeja Pintar, Stojan Potrč, Nataša Smrekar, Monika Sonc, Maja Šeruga, Petra Tavčar, Igor Virant, 2021, professional article Keywords: kronična odpoved prebavil, zdravljenje, onkološko zdravljenje
Published in DiRROS: 11.06.2021; Views: 1506; Downloads: 399
Full text (135,03 KB) |
